Pancreatic ductal adenocarcinoma, or PDAC, is a deadly form of cancer that often resists standard treatments. A major reason for this resistance is the tumor microenvironment, a protective shield made of immune cells that hides the cancer from the body's defenses. Among these cells are tumor-associated neutrophils, which are white blood cells that can change their behavior to either attack the tumor or help it grow. This systematic review looks closely at how these cells develop, the different types they become, and the complex signals they use to talk to other cells in the tumor.
The researchers found that these neutrophils are pivotal regulators in the tumor's environment. They can switch into different forms, some that fight the cancer and others that fuel its spread. Key pathways driving this behavior include TGF-beta and CXCR2, which act like communication lines between the cells. Scientists are now looking at three main strategies to fight back: stopping the cancer from recruiting these cells, changing how the cells function, or breaking the suppression they create.
This review does not report specific safety data, patient counts, or trial results because it summarizes existing knowledge rather than testing a new drug. It is important to remember that while these findings offer promising perspectives for overcoming therapeutic resistance, they are not yet a guaranteed solution. The science is still unfolding, and patients should discuss these emerging ideas with their doctors to understand what they mean for their specific situation.